An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants

A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of BMS-986224 in Participants With Varying Degrees of Renal Function

The purpose of this study is to investigate the experimental medication BMS-986224 in participants with varying levels of renal function.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• BMI ≥18 and ≤ 35kg/m2
• Systolic blood pressure >100 mmHg

Exclusion Criteria:

• Women of childbearing potential or women who are currently pregnant
• Clinically relevant abnormal medical history, abnormal findings on physical examination, vital signs, ECG, or laboratory tests at screening that the investigator judges as likely to interfere with the objectives of the trial or the safety of the volunteer
• Current or recent (within 3 months of study treatment administration) gastrointestinal disease that could affect absorption

Other protocol defined inclusion/exclusion criteria could apply